Bandron Injection (Ibandronic Acid Sodium Hydrate)

Adult administration

3mg administered intravenously once every 3 months over 15 - 30 seconds.

This medication must be administered intravenously and caution is required as administering into the arteries or perivascular areas may cause tissue damage. Patients with hypersensitivity to this medication or its ingredients and those with untreated hypocalcemia should not be administered this drug. Some patients may experience gastrointestinal adverse reactions such as gastritis, diarrhea, abdominal pain, dyspepsia, nausea, and constipation during the use of this medication. Musculoskeletal side effects may include muscle pain, joint pain, and musculoskeletal pain, while systemic side effects may include influenza-like symptoms and fatigue. Neurological and skin reactions such as headaches and rashes have also been reported. Rarely, serious allergic reactions such as anaphylaxis may occur during administration of this medication, requiring immediate medical attention. This medication can temporarily lower serum calcium levels; therefore, hypocalcemia and disorders of bone and mineral metabolism should be treated before administration, and it is important to ensure sufficient intake of calcium and vitamin D. For patients undergoing dental treatment or with poor oral hygiene, there is a risk of jaw osteonecrosis, so it is advisable to have an oral examination before administration. During the administration of this medication, excessive dental procedures should be avoided, as surgical procedures in the case of jaw osteonecrosis may worsen the condition. Additionally, bisphosphonates, including this medication, have been reported to be associated with bone-related abnormalities such as osteonecrosis of the external auditory canal and atypical femoral fractures, so immediate evaluation is necessary if pain is experienced in the thigh or groin. This medication is not metabolized in the liver and is mainly excreted through the kidneys, so patients with impaired kidney function require regular monitoring. It is recommended that women who are pregnant or breastfeeding do not use this medication, and the safety and efficacy in patients under 18 years of age have not been established. Overdosage may lead to toxicity in the kidneys and liver, necessitating careful monitoring and appropriate treatment if symptoms such as hypocalcemia occur. This medication should not be mixed with calcium-containing solutions or other intravenous drugs and must be administered as an intravenous injection only. Used injection needles and syringes should not be reused and should be disposed of safely.

Serious side effects

Hives, angioedema, facial swelling/edema, anaphylactic reaction/shock, severe allergic reaction, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, severe skin adverse reactions, angioedema, allergic reactions, respiratory distress, exacerbation of asthma, breathing problems, multiple organ failure, death, severe neurological symptoms (including optic atrophy, lower motor neuron lesions, tremors), acute renal failure, severe edema or urination abnormalities (increased blood pressure.

Mild side effects

Gastritis, diarrhea, abdominal pain, dyspepsia, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, influenza-like illness (including joint pain, muscle pain, fever, chills, fatigue, nausea, loss of appetite, bone pain), fatigue, headache, rash, bone pain, weakness, injection site reactions, phlebitis/thrombophlebitis, dizziness, insomnia, anxiety, tinnitus, hearing loss, lipoma, ocular hemorrhage, heart failure, urination disorders, hematuria, skin exfoliation, optic nerve.

This medication should be stored in a sealed container to prevent contact with air, at room temperature between 1 and 30 degrees Celsius. Therefore, it is important to avoid extremely hot or cold places and store it in an area that maintains an appropriate temperature.

Appearance

An injection solution that is a colorless, transparent liquid contained in a colorless, transparent glass prefilled syringe, with a single-use needle attached.

Package unit

1 vial of 3mL